Cargando…

Correction to: Thyrotropin receptor antibodies and Graves’ orbitopathy

Detalles Bibliográficos
Autores principales:	Diana, T., Ponto, K. A., Kahaly, G. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741683/ https://www.ncbi.nlm.nih.gov/pubmed/34302685 http://dx.doi.org/10.1007/s40618-021-01632-2

Ejemplares similares

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Stimulatory Thyrotropin Receptor Antibodies Are a Biomarker for Graves’ Orbitopathy
por: George, Augustine, et al.
Publicado: (2021)

Sensitivity of three thyrotropin receptor antibody assays in thyroid-associated orbitopathy
por: Sarić-Matutinović, Marija, et al.
Publicado: (2022)

Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease
por: Kahaly, George J, et al.
Publicado: (2019)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

Thyrotropin Receptor Blocking Antibodies
por: Diana, Tanja, et al.
Publicado: (2018)

SAT-557 Functional Thyrotropin Receptor Antibodies Confirm a Novel Graves' Disease Animal Model
por: Diana, Tanja, et al.
Publicado: (2019)

Glucocorticoids in Graves’ orbitopathy: mechanisms of action and clinical application
por: Längericht, Jan, et al.
Publicado: (2020)

SAT-429 Systemic Safety Analysis of Mycophenolate in Graves’ Orbitopathy
por: Lee, Alan C H, et al.
Publicado: (2020)

ELF3-induced miR-182 inhibits adipogenic differentiation in Graves’ orbitopathy by targeting thyrotropin receptor
por: Wang, Sha, et al.
Publicado: (2023)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

SAT-554 Teprotumumab in Graves' Orbitopathy: Extended Outcome Analyses
por: Kahaly, George, et al.
Publicado: (2019)

MON-583 Functional Thyrotropin Receptor Antibodies in Pregnant Women with Thyroid Autoimmunity
por: Diana, Tanja, et al.
Publicado: (2019)

Cut-Off Value of Thyrotropin-Receptor Antibodies in Grave’s Disease in Basrah
por: Radhi, Maher A, et al.
Publicado: (2023)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

Versorgungsrelevante Daten einer interdisziplinären Sprechstunde für endokrine Orbitopathie
por: Ponto, Katharina A., et al.
Publicado: (2020)

Thyroid Receptor Antibody and the Development of Graves’ Orbitopathy: Clinical Experience of using Radioiodine Ablation in the Management of Graves’ Orbitopathy in post-iodine ablation hypothyroid patient
por: Christina, Edelyn, et al.
Publicado: (2023)

Correction: Influence of orbital morphology on proptosis reduction and ocular motility after decompression surgery in patients with Graves' orbitopathy
Publicado: (2019)

Thyrotropin Binding Inhibiting Antibody (TBIAb) in Graves’ Disease
por: Cho, Won Yong, et al.
Publicado: (1988)

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy
por: Hou, Jueyu, et al.
Publicado: (2021)

Correlation between TSH Receptor Antibody Assays and Clinical Manifestations of Graves' Orbitopathy
por: Jang, Sun Young, et al.
Publicado: (2013)

Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Current Knowledge on Graves’ Orbitopathy
por: Gontarz-Nowak, Katarzyna, et al.
Publicado: (2020)

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Rapamycin improves Graves’ orbitopathy by suppressing CD4(+) cytotoxic T lymphocytes
por: Zhang, Meng, et al.
Publicado: (2023)

TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy
por: Siderova, Mira, et al.
Publicado: (2018)

Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study
por: Pearce, Simon H.S., et al.
Publicado: (2019)

Changes in the Properties of the Thyrotropin Receptor Antibody in Patients with Graves’ Disease after Radioiodine Treatment
por: Cho, Bo Youn, et al.
Publicado: (1990)

Evaluation of the diagnostic performance of thyroid‐stimulating immunoglobulin and thyrotropin receptor antibodies for Graves' disease
por: Xu, Shiji, et al.
Publicado: (2023)

Comparison Between Thyroid Stimulating Immunoglobulin and TSH-Receptor Antibodies in the Management of Graves’ Orbitopathy
por: Khamisi, Selwan, et al.
Publicado: (2023)

Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves’ orbitopathy
por: Park, Jungyul, et al.
Publicado: (2023)

Thyrotropin Receptor Epitope and Human Leukocyte Antigen in Graves’ Disease
por: Inaba, Hidefumi, et al.
Publicado: (2016)

Reply to Drs. Kiaei and Molinaro Regarding the Publication “Comparison of a Bridge Immunoassay with Two Bioassays for Thyrotropin Receptor Antibody Detection and Differentiation”
por: Allelein, Stephanie, et al.
Publicado: (2020)

Graves′ orbitopathy: Management of difficult cases
por: Wiersinga, Wilmar M.
Publicado: (2012)

Endoscopic orbital decompression for Graves’ orbitopathy
por: Lal, Priti, et al.
Publicado: (2013)

Current concepts regarding Graves’ orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2022)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Significance of HLA in the development of Graves’ orbitopathy
por: Stasiak, Magdalena, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1aec63i79fvhass0si6ep1gqng